Life Biosciences has been among those struggling companies. Initially formed in 2017, it at first had a strategy of launching subsidiaries, each intended to pursue one aspect of the aging problem. But after these made limited progress, in 2021 it hired a new CEO, Jerry McLaughlin, who has refocused its efforts on Sinclair’s mouse vision results and the push toward a human trial.
The company has discussed the possibility of reprogramming other organs, including the brain. And Ringel, like Sinclair, entertains the idea that someday even whole-body rejuvenation might be feasible. But for now, it’s better to think of the study as a proof of concept that’s still far from a fountain of youth. “The optimistic case is this solves some blindness for certain people and catalyzes work in other indications,” says Pfleger, the investor. “It’s not like your doctor will be writing a prescription for a pill that will rejuvenate you.”
Life’s treatment also relies on an antibiotic switching mechanism that, while often used in lab animals, hasn’t been tried in humans before. Since the switch is built from gene components taken from E. coli and the herpes virus, it’s possible that it could cause an immune reaction in humans, scientists say.
“I was always thinking that for widespread use you might need a different system,” says Noah Davidsohn, who helped Sinclair implement the technique and is now chief scientist at a different company, Rejuvenate Bio. And Life’s choice of reprogramming factors—it’s picked three, which go by the acronym OSK—may also be risky. They are expected to turn on hundreds of other genes, and in some circumstances the combination can cause cells to revert to a very primitive, stem-cell-like state.
Other companies studying reprogramming say their focus is on researching which genes to use, in order to achieve time reversal without unwanted side effects. New Limit, which has been carrying out an extensive search for such genes, says it won’t be ready for a human study for two years. At Shift, experiments on animals are only beginning now.
“Are their factors the best version of rejuvenation? We don’t think they are. I think they are working with what they’ve got,” Daniel Ives, the CEO of Shift, says of Life Biosciences. “But I think they’re way ahead of anybody else in terms of getting into humans. They have found a route forward in the eye, which is a nice self-contained system. If it goes wrong, you’ve still got one left.”
